FACT SHEET: Biden-Harris Administration Announces Allocation Plan for 55 Million Doses to be Shared Globally
JUNE 21, 2021 • STATEMENTS AND RELEASES
These doses are the remaining part of the 80 million President Biden pledged to allocate by the end of June
Today, the Biden-Harris Administration is announcing the distribution list for 55 million of the 80 million doses of America’s own vaccine supply President Biden has pledged to allocate by the end of June in service of ending the pandemic globally. As we continue to fight the COVID-19 pandemic at home and work to end the pandemic worldwide, President Biden has promised that the United States will be an arsenal of vaccines for the world. Part of that plan is donating vaccine from our domestic supply, and the President has pledged 80 million doses to be allocated by the end of June. Earlier this month, the Administration announced the plan for the first 25 million doses that we have begun shipping, and today’s announcement completes the list for the remaining 55 million doses. For all of these doses, those most at risk, such as health care workers, should be prioritized, based on national vaccine plans.
In addition to sharing doses from our own vaccine supply, the Biden-Harris Administration is also committed to working with our U.S. manufacturers to produce more vaccine to share with the world. To that end, ahead of the G7, President Biden announced that the U.S. will purchase half a billion Pfizer doses and donate them to 92 low- and lower middle-income countries and members of the African Union. In total, the G7+ agreed to provide an additional more than 1 billion doses starting summer 2021. In addition, the U.S. is committed to expanding local production of vaccines, and through our Quad partnership and the International Development Finance Corporation’s support for vaccine manufacturing, more than 1 billion doses will be produced in Africa and India in 2021 and 2022. This vaccine strategy is a vital component of our overall global effort to lead the world in the fight to defeat COVID-19 and to achieve global health security.
For these 80 million doses, the U.S. will share 75% through COVAX and 25% will be targeted to help deal with surges around the world. Our goals are to increase global COVID-19 vaccination coverage, prepare for surges and prioritize healthcare workers and other vulnerable populations based on public health data and acknowledged best practice, and help our neighbors and other countries in need. And, as we have previously stated, the United States will not use its vaccines to secure favors from other countries.
Based on this framework and pending legal and regulatory approvals, the allocation plan for these 55 million doses will be as follows:
- Approximately 41 million will be shared through COVAX, with the following allocations:
- Approximately 14 million for Latin America and the Caribbean to the following: Brazil, Argentina, Colombia, Peru, Ecuador, Paraguay, Bolivia, Uruguay, Guatemala, El Salvador, Honduras, Haiti, and other Caribbean Community (CARICOM) countries, Dominican Republic, Panama, and Costa Rica.
- Approximately 16 million for Asia to the following: India, Nepal, Bangladesh, Pakistan, Sri Lanka, Afghanistan, Maldives, Bhutan, Philippines, Vietnam, Indonesia, Thailand, Malaysia, Laos, Papua New Guinea, Taiwan, Cambodia, and the Pacific Islands.
- Approximately 10 million for Africa to be shared with countries that will be selected in coordination with the African Union.
- Approximately 14 million – or 25% of these 55 million vaccines – will be shared with regional priorities and other recipients, such as: Colombia, Argentina, Haiti, other CARICOM countries, Dominican Republic, Costa Rica, Panama, Afghanistan, Bangladesh, Pakistan, Philippines, Vietnam, Indonesia, South Africa, Nigeria, Kenya, Ghana, Cabo Verde, Egypt, Jordan, Iraq, Yemen, Tunisia, Oman, West Bank and Gaza, Ukraine, Kosovo, Georgia, Moldova, and Bosnia.
Sharing millions of U.S. vaccines with other countries signals a major commitment by the U.S. Government. Just like we have in our domestic response, we will move as expeditiously as possible, while abiding by U.S. and host country regulatory and legal requirements, to facilitate the safe and secure transport of vaccines across international borders. This will take time, but the President has directed the Administration to use all the levers of the U.S. government to protect individuals from this virus as quickly as possible. The specific vaccines and amounts will be determined and shared as the administration works through the logistical, regulatory and other parameters particular to each region and country.